



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/725,037 | 12/02/2003 | Mark Zoller | 54074D4 | 4720 |
| 21967 | 7590 | 09/21/2006 | EXAMINER | |
| HUNTON & WILLIAMS LLP INTELLECTUAL PROPERTY DEPARTMENT 1900 K STREET, N.W. SUITE 1200 WASHINGTON, DC 20006-1109 | | | LANDSMAN, ROBERT S | |
| | | ART UNIT | PAPER NUMBER | |
| | | 1647 | | |

DATE MAILED: 09/21/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|------------------------------------|-------------------------|--|
| Office Action Summary | Application No. | Applicant(s) | |
| | 10/725,037 | ZOLLER ET AL. | |
| | Examiner Robert Landsman | Art Unit 1647 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 12/203 (Preliminary Amendment) + 10/12/04 + 9/6/05
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 194-229 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 194-229 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

| | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>9/1/06</u> . | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

*10/12/04
9/17/06*

1. Formal Matters

- A. The Preliminary Amendment filed 12/2/03 has been entered into the record.
- B. Claims 194-229 are pending and are the subject of this Office Action.
- C. The Information Disclosure Statement filed 9/1/06 has been entered into the record.

2. Oath

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because: the inventor Jon Alder did not sign the Oath.

3. Specification

- A. The specification is objected to since the status of applications in the first line of the specification should be updated.
- B. It is noted that SEQ ID NO:10 of the instant application is 2519 bases, whereas the corresponding SEQ ID NO:3 in 09/897,427 is 2520 bases.
- C. It is noted that related application US20020160424 claims benefit to US Provisional Application 60,280,606. This appears to be incorrect.
- D. The drawings show a Figure 3C. However, this Figure is not referenced in the Brief Description of the Figures.
- E. The Brief Description of Figure 16 does not recite "Figures 16 A and B," for example, in order to correspond to the actual Figures.
- F. The status of application 09/984,292 on page 15 ([0071]) should be updated.

4. Claim Objections

A. Claims 220 and 221 are objected to since the syntax could be improved. Applicants should consider amending the phrase “comprised in” since proteins are not actually comprised in membranes inasmuch as membranes comprise the receptor.

B. The syntax of claim 229 could be improved by replacing the word “which” with “wherein” and replacing the word “such” with “said.”

5. Claim Rejections - 35 USC § 112, first paragraph – scope of enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

A. Claims 194-229 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the heterodimer of SEQ ID NO:6 and 7 (encoded by SEQ ID NO:9 and 10), does not reasonably provide enablement for all heteromeric sweet taste receptors, including those which are at least 90% identical to SEQ ID NO:6 or 7, or for those which hybridize to SEQ ID NO:9 or 10. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

In In re Wands, 8USPQ2d, 1400 (CAFC 1988) page 1404, the factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

First, the breadth of the claims is excessive with regard to claiming all heteromeric T1R2/T1R3 taste receptors which are activated by sweet taste, including those from **any and all species**. Applicants have only identified SEQ ID NO:6 and 7 form a dimer and are activated by sweet taste. Similarly, the breadth is excessive with regard to taste receptors encoded by polynucleotides which “hybridize” under stringent conditions to that of SEQ ID NO:9 or 10, or which encode proteins which are “at least 90%” identical to SEQ ID NO:6 or 7, or “fragments” thereof. Nucleic acid molecules which “hybridize” to those polynucleotides would have one or more nucleic acid substitutions, deletions, insertions and/or additions to said polynucleotides. Similarly, proteins which are “at least 90%” identical to the claimed

proteins would have one or more amino acid substitutions, deletions, insertions and/or additions to the claimed proteins.

Applicants provide no guidance or working examples of nucleic acid molecules which hybridize to SEQ ID NO:9 or 10, of proteins which are “at least 90%” identical to SEQ ID NO:6, or 7, or “fragments” thereof. Furthermore, it is not predictable to one of ordinary skill in the art how to make a functional T1R2/T1R3 heterodimer other than that comprising the full-length SEQ ID NO:6 and 7. It is noted that, for example, claims 199, 206, etc. recite only one of the disclosed members of the heterodimer.

In summary, the breadth of the claims is excessive with regard to Applicants claiming all nucleic acids which hybridize to SEQ ID NO:9 or 10, for proteins which are at least 90% identical to SEQ ID NO:6 or 7, or for fragments thereof. There is also a lack of guidance and working examples of these nucleic acid molecules and proteins. These factors, along with the lack of predictability to one of ordinary skill in the art as to how to make a functional T1R2/T1R3 heterodimer other than that comprising the full-length SEQ ID NO:6 and 7 leads the Examiner to hold that undue experimentation is necessary to practice the invention as claimed.

6. Claim Rejections - 35 USC § 112, first paragraph – written description

A. Claims 194-229 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

These are genus claims. The specification only describes the T1R2/T1R3 heterodimer comprising SEQ ID NO:6 and 7. Heterodimers from **any other species**, or which are “**at least 90% identical**” to SEQ ID NO:6 or 7 would have one or more amino acid substitutions, deletions, insertions and/or additions to these proteins and have not been described. Similarly, nucleic acid molecules which “**hybridize**” to those polynucleotides of SEQ ID NO:9 or 10 would have one or more nucleic acid substitutions, deletions, insertions and/or additions to said polynucleotides. Similarly, Applicants have not described which residues are critical for protein function. Therefore, proteins which are “fragments” of proteins whose encoding polynucleotides hybridize to SEQ ID NO:9 and 10 have also not been described.

The specification and claims do not indicate what distinguishing attributes are shared by the members of the genus. Thus the scope of the claims includes numerous structural variants, and the genus is highly variant because a significant number of structural differences between genus members is

permitted. The specification and claims do not provide any guidance as to what changes should be made. Structural features that could distinguish compounds in the genus from others in the nucleic acid or protein class are missing from the disclosure. No common structural attributes identify the members of the genus. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is what is needed. Since the disclosure fails to describe the common attributes or characteristics that identify members of the genus, and because the genus is highly variant, SEQ ID NO:6, 7, 9 and 10, or molecules which hybridize to the polynucleotides encoding these SEQ ID NOs (which could be at least thousands of molecules) alone are insufficient to describe the genus. One of skill in the art would reasonable conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, Applicant was not in possession of the claimed genus at the time the invention was made.

7. Claim Rejections - 35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

A. Claims 194-229 are indefinite because the elements recited in the claim do not constitute proper Markush groups. The claims are indefinite in the alternative use of "and/or" because it is not clear what controls which of these limitations. See MPEP § 2173.05(h).

B. Claims 194-229 are indefinite since the metes and bounds of "activation are unclear."

C. Claims 199-206, 209-216 and 229 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "contained in" is unclear. It is not understood if the claim refers to the full-length of the claimed SEQ ID NO, or a fragment thereof which encodes the functional receptor, for which the specification has not described.

D. Claims 207 and 217 are vague and indefinite since the claim recites "stringent conditions." It is not known what these conditions are. Nucleic acid molecules which hybridize under conditions of "low" stringency would not necessarily hybridize under conditions of "high" stringency. Furthermore, not all

conditions of “high” or “low” stringency, for example, are the same. Therefore, it is required that Applicants amend the claims to recite the exact hybridization conditions without using indefinite phrases such as “*for example*” **without adding new matter**.

E. Claims 207 and 217 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase “associated with” is unclear. It is not understood in what manner T1R2 is “associated with” T1R3.

F. Claim 224 recites the limitation “label.” There is insufficient antecedent basis for this limitation in the claim. It is believed claim 224 should depend from claim 223 instead of 225.

8. Provisional Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

A. Claims 194-229 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 194-234 of copending Application No. 10/725,103; claims 194-235 of copending Application No. 10/725,472 and claims 194-256 of copending Application No. 10/725,475. Although the conflicting claims are not identical, they are not patentably distinct from each other because The instant application recites the heteromeric taste receptors. The ‘103 application recites a recombinant cell comprising this dimer. The ‘472 application recites a method of expressing the dimer.

Art Unit: 1647

The '475 application recites a method of screening compounds using the dimer. Methods of making and using the dimer are obvious.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

8. Prior Art

A. No art rejection is being made since, even though the claimed sequences may have been known at the time of filing of the instant application (e.g. US20030036089), no prior art reference teaches the claimed T1R heterodimers, or that they modulate sweet taste. It is noted that the present invention is only being given priority to 09/897,427 (July 3, 2001).

9. Conclusion

A. No claim is allowable.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (571) 272-0888. The examiner can normally be reached on M-Th 10 AM – 7 PM (eastern).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Robert Landsman
Primary Examiner
Art Unit 1647